Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.West Pharmaceutical Services has concluded an agreement with Nektar Therapeutics relating to the manufacture and assembly of components for the Exubera inhalable insulin device.
Subscribe to our email newsletter
Under the new agreement, West will be reimbursed for facility, inventory, raw materials and personnel costs at levels that are consistent with the company’s previously announced expectations. In order to assure Nektar of a reliable source of supply as it resolves its plans for the Exubera product, West has agreed to maintain the facility for a period of between two and 10 months.